Quantcast

Global Non-Alcoholic Steatohepatitis (NASH) Market is Expected to Reach $1.6 Billion by 2020 – Allied Market Research

August 6, 2014

PORTLAND, Oregon, August 6, 2014 /PRNewswire/ –

A new report by Allied Market Research entitled, “Nonalcoholic Steatohepatitis Market
(Pipeline analysis, drug class and Geography) Global Size, Industry Analysis, Trends,
Opportunities, Growth and Forecast, 2013 – 2020″, indicates that the global nonalcoholic
steatohepatitis (NASH) market would reach $1.6 billion by 2020 registering CAGR of 25.6%
from 2014 to 2020. The high prevalence of Type II diabetes and obesity, which lead to NASH
and other non-alcoholic fatty liver diseases (NAFLD), would boost market growth. North
America’s heightened focus on NASH research has resulted in it accounting for nearly half
of the global market. It is also the region with the maximum occurrences of NASH and other
non-alcoholic fatty liver diseases. Europe ranks second in terms of the prevalence of
NASH.

Get full access of the report with TOC at

http://www.alliedmarketresearch.com/nonalcoholic-steatohepatitis-NASH-market

The number of patients living with the diabetes worldwide is expected to soar from 371
million in 2012 to 552 million by 2030. This suggests that by 2030, there will be 3 new
cases of diabetes every 10 seconds. “The rampant growth of diabetes and obesity has
prompted pharmaceutical manufacturers to seek out novel pharmaceutical solutions to tap
promising potential in NASH,” states AMR analyst Roshan Deshmukh. “Instrumental
initiatives and increasing clinical trials for the development of novel NASH therapeutics
will steer its faster commercialization,” adds the analyst. Concerted efforts in research
and development from companies such as Genfit, Gilead Science, Novo Nordisk, Raptor
Pharmaceutical Corp. and Intercepts Pharmaceuticals would help them gain core competencies
in this market. Dainippon Sumitomo Pharma (DSP), a partner of Intercept Pharmaceuticals,
initiated a phase 2 clinical trial to test the safety and efficacy of daily dose of
Obeticholic Acid (OCA) in 200 adult NASH patients. The trial is expected to be completed
in the first half of 2016. Thus, prevalence of diabetes and research and developments in
the field of fatty liver disease therapeutics would supplement market growth in the next
six years.

AMR analysis suggests that commercialization of NASH therapeutics and diagnostics in
the market would not only lower healthcare expenses of patients but would also increase
its (NASH therapeutics) share in the overall fatty liver disease therapeutics market.
Commercialization of GFT505 and OCA would give the NASH therapeutics market a boost as
these drugs are meant to specifically treat fatty liver diseases. Additionally, the
popularity of diagnostic biomarker technologies in the diagnosis of liver diseases would
also accelerate market growth. However, presence of stringent regulatory guidelines and
insufficient information regarding the pathophysiology of NASH tissue is considered to
restraint in commercialization of potential drugs.

See Biosimilars/Follow-on-Biologics Market report at

http://www.alliedmarketresearch.com/biosimilars-market

In Europe, NASH is most prevalent in Germany, Italy, Spain, France and the United
Kingdom. Intercept Pharmaceuticals, in collaboration with DSP, is developing obeticholic
acid for commercialization in the United States and European countries. This drug is
expected to receive commercial approval by the end 2017. Developing economies,
particularly in the Asia-Pacific region, are the fastest growing markets for NASH
therapeutics and are expected to have a double digit growth rate during the analysis
period. The chief reason behind this growth is the high prevalence of nonalcoholic fatty
liver diseases in densely populated countries such as China, Japan and Korea with
prevalence rate of 12% to 24% per year. In western industrialized countries, the
prevalence rate is estimated to be approximately 20% to 40%.

Browse all pharmaceutical market reports at

http://www.alliedmarketresearch.com/pharmaceuticals-market-report

Most giant biopharmaceutical manufacturing companies are currently attempting to
develop novel therapeutics for the treatment of NASH. These companies are adopting
clinical trials and approval as key strategies in order to gain competitive edge. Most of
these companies operate from the United States and are collaborating with private research
and academic institutes to conduct clinical trials. Key companies profiled in the report
are: Genfit, Gilead Science, Novo Nordisk, Intercepts Pharmaceuticals, Enzo Biochem, Inc.
and Raptor Pharmaceutical Corp.

About Us:

Allied Market Research (AMR) is a full-service market research and business-consulting
wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides
global enterprises as well as medium and small businesses with unmatched quality of
“Market Research Reports” and “Business Intelligence Solutions”. AMR has a targeted view
to provide business insights and consulting to assist its clients to make strategic
business decisions and achieve sustainable growth in their respective market domain.

We are in professional corporate relations with various companies and this helps us in
digging out market data that helps us generate accurate research data tables and confirms
utmost accuracy in our market forecasting. Each and every data presented in the reports
published by us is extracted through primary interviews with top officials from leading
companies of domain concerned. Our secondary data procurement methodology includes deep
online and offline research and discussion with knowledgeable professionals and analysts
in the industry.

        Contact:
        Sona Padman
        5320 SW Macadam Avenue,
        Suite 100, Portland, OR 97239
        United States
        Direct: +1(617)674-4143
        Toll Free: +1(855)711-1555 (U.S. & Canada)
        Fax: +1(855)550-5975
        Web: http://www.alliedmarketresearch.com

SOURCE Allied Market Research


Source: PR Newswire



comments powered by Disqus